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Head and neck squamous cell carcinoma is the 6th most common malignancy 
worldwide. Recently, a link between cancer and inflammation has been found. Mediating 
this relationship are the chemotactic cytokines known as chemokines. CXCL8 (Interleukin-
8), a CXC ELR+ Chemokine mainly responsible for neutrophil chemoattraction, has been 
implicated in increased tumor proliferation, migration and angiogenesis. The current study 
tests the effects of CXCL8 on the tumor proliferation and metastasis. By genetically 
xii 
modifying cells to knockdown or overexpress the CXCL8 gene we tested its biological role 
in head and neck cancer progression. Overexpression of CXCL8 in HN4 tumor cells with 
low endogenous CXCL8 levels was found to increase tumor growth, as judged by cell 
counting and MTT assays. Conversely, RNAi-mediated knockdown of CXCL8 expression 
in HN12 cells, which express high levels of this chemokine, resulted in a decrease in 
proliferation. Similarly, overexpression of CXCL8 enhanced migration of HN4 cells in 
vitro, while knockdown inhibited HN12 cell migration and invasion through a basement 
membrane substitute. Taken together, these findings support the hypothesis that CXCL8 
affects multiple processes involved in head and neck cancer tumor progression. The data 
suggest that CXCL8 is a potential therapeutic target for head and neck, and other, cancers.  
 
 1 
 
 
 
 
 Introduction and Background 
 
 
1.1  Cancer 
 Worldwide, out of every 100,000 people, anywhere from 100 to 300 will die of 
cancer and approximately one fifth of the deaths in the United States each year are cancer 
related (Lodish, et al., 2004). Of these vast numbers, head and neck cancer accounts for 
about six to seven percent of new cancers (McMahon and Chen, 2003). 40,000 people in 
the United States and 500,000 people worldwide are diagnosed with head and neck cancer 
each year (Kim and Califano, 2004). Diagnosis and treatment of head and neck cancer has 
had many advances in the past 20 years, unfortunately survival rates have not improved 
very significantly (McMahon and Chen, 2003). The 5-year survival rate has remained at 
approximately 50% with some sites and more advanced lesions having considerably poorer 
outcomes (Kim and Califano, 2004). Head and neck cancers involve four anatomical areas 
of the body: the oral cavity, oropharynx, hypopharynx, and larynx. Since all of these areas 
are covered by squamous mucosa, the most common type of malignancy (accounting for 
approximately 90%) is squamous cell carcinomas (McMahon and Chen, 2003). 
 Cancer is the result of genetic mutations occurring in normal cells, which leads to 
alterations in their normal physiological processes including proliferation, differentiation, 
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apoptosis and motility (Yeudall and Miyazaki, 2007). These mutations occur in two large 
classes of genes: proto-oncogenes and tumor suppressor genes (Kim and Califano, 2004; 
Lodish, et al., 2004). Proto-oncogenes normally have a proliferative effect on cells. When 
a gain-of-function mutation occurs in these genes they may become constitutively active 
leading to the cancer phenotype (Kim and Califano, 2004; Lodish, et al., 2004). On the 
other hand, tumor suppressor genes are normally regulatory and anti-proliferative. A loss-
of-function mutation in these genes causes them to lose the ability to regulate proliferation, 
and similarly to the proto-oncogenes, they too may develop a cancer phenotype (Kim and 
Califano, 2004; Lodish, et al., 2004). 
 These mutations can occur via environmental influences or genetic factors 
(McMahon and Chen, 2003). Environmental factors are typically carcinogens, such as 
certain chemicals or ultraviolet radiation that humans are exposed to. Certain viruses, such 
as human papillomavirus (HPV) can also cause cancer. The most preventable 
environmental risk factor for HNSCC is tobacco use, which includes cigarette smoke and 
smokeless tobacco. (McMahon and Chen, 2003; La Vecchia, et al., 1997). Also included in 
this preventable sub-grouping is alcohol. It has been found that the risk for cancer by 
alcohol and tobacco together is greater than multiplicative (La Vecchia, et al., 1997). It 
was also reported that the relative risk for HNSCC among tobacco and alcohol abusers is 
approximately 20 times great than those who use neither (McMahon and Chen, 2003; La 
Vecchia, et al.,1997). Several theories have been developed as to the role that alcohol plays 
in this duo, which includes its function as a solvent, facilitating the passage of carcinogens 
into cells or its effect of increased liver metabolism to activate carcinogenic substances (La 
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Vecchia, et al., 1997). Inherited genes can also lead to host susceptibility factors, such as 
how efficiently carcinogen metabolism occurs in cells and the cells ability to repair DNA 
damage (McMahon and Chen, 2003).  
1.2  Cancer and Inflammation 
 More recently, another possible cause of cancer has been found: inflammation. This 
link is beginning to have implications for the treatment and possible prevention of cancer 
(Balkwill and Mantovani, 2001). Inflammation is a normal part of an organism’s reaction 
to various stimuli, with the function of counteracting them. Acute inflammation is a 
beneficial response that can be therapeutic if it is self-limiting or manifested for a short 
period of time (Lawrence, 2007; Aggarwal, et al., 2006). It involves the recruitment of 
polymorphonuclear granulocytes followed closely by monocytes, which differentiate into 
macrophages. This process is usually initiated by the activation of resident macrophages, 
which release proinflammatory molecules such as eicosanoids, cytokines, chemokines and 
proteases, which recruit and activate leukocytes (Lawrence, 2002). On the other hand 
chronic, or long-lasting, inflammation may be harmful and can lead to disease. This 
perseverance can be due to a prolonged inflammatory stimulus or the dysregulation of an 
organism’s own anti-inflammatory mechanisms (Lawrence, 2007; Aggarwal, et al., 2006). 
Chronic inflammation has been found to play a key role in many diseases, including 
cardiovascular diseases, cancer, diabetes, arthritis, Alzheimer’s disease, pulmonary 
diseases and autoimmune diseases (Aggarwal, 2004). More specifically to cancer however, 
studies have shown that chronic inflammation has been linked to many key steps which aid 
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in the progression of tumorigenesis, including cellular transformation, survival, 
proliferation, invasion, neovascularization and metastasis (Mantovani, 2005; Coussens and 
Werb, 2002). Also, supporting this idea is the fact that tumors are not made up completely 
of transformed cells, but that as much as 80% can be made up of stromal cells and 
inflammatory cells that have not been genetically modified (Leek, 1996).  
 
 
Figure 1: Chemokine production. Chronic inflammation, tissue damage and chronic 
infection may stimulate cytokines and chemokines that contribute to development of 
malignant disease (Balkwill and Mantovani, 2001). 
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1.3  Chemokines 
 
  One of the major groups of pro-inflammatory molecules that have been 
implemented in the progression of cancer are the chemokines. Chemokines, or chemotactic 
cytokines, are part of a large multifunctional family of molecules that induce the migration 
of leukocytes, and are induced by inflammatory cytokines, growth factors and pathogenic 
stimuli (Laing and Secombes, 2004; Balkwill, 2004). They are small molecules ranging 
anywhere from 8-10 kD in size (Laing and Secombes, 2004; Balkwill, 2004; Wilson and 
Slettenaar, 2006). Some chemokines are homeostatic in nature and are produced and 
secreted constitutively. Others are produced by cells during infection or following a pro-
inflammatory stimulus (Laing and Secombes, 2004). Signaling by chemokines typically 
results in the transcription of various genes that are involved in many tumorigenic 
activities such as cell invasion, motility, extracellular matrix interactions and survival 
(Balkwill, 2004).   
 Chemokines are structurally divided into four main categories according to the 
number and spacing of the first two cysteine residues at the N-terminal end of the protein: 
C, CC, CXC and CX3C (Laing and Secombes, 2004; Balkwill, 2004; Wilson and 
Slettenaar, 2006). 
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Figure 2: Chemokine classes. Representation of C, CC, CXC and CX3C 
chemokine classes. Diagram shows consecutive cysteine residues, peptide chain and 
disulphide bridges 
 
 
The ELR+ CXC subgroup includes CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
CXCL7, CXCL8 and CXCL15. The function of these CXC chemokines is to promote the 
adherence and migration of neutrophils closer to inflammatory sites. They also have 
angiogenic and chemotactic properties for endothelial cells (Laing and Secombes, 2004). 
The ELR- CXC subgroup includes CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, 
CXCL13, CXCL14 and CXCL16. These chemokines are responsible for attracting 
lymphocytes and monocytes, but unlike ELR+ CXC chemokines, they have poor 
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chemotactic ability for neutrophils. Also opposite to the ELR+ CXC chemokines, is this 
subgroup’s ability to inhibit angiogenesis because most are believed to be angiostatic 
(Laing and Secombes, 2004). CC Chemokines are responsible for the attraction of 
mononuclear cells (macrophages) that are involved in either homeostatic or pro-
inflammatory mechanisms as well as both chemoattractant and immunomodulatory roles. 
(Laing and Secombes, 2004; Yeudall and Miyazaki, 2007). The C and CX3C groups are 
not as common and do not play as large of a role in inflammation and cancer as the CC and 
CXC groups. 
 Most chemokines, despite their differences in structure, exert their effects by 
binding to seven transmembrane domain G protein-coupled receptors (GPCRs). The CC 
chemokines bind to CCRs, the CXC chemokines bind to CXCRs and the C and CX3C 
chemokines bind to CX3CRs and XCRs (Yeudall and Miyazaki, 2007). There is 
considerable redundancy in the system with many chemokines binding to more than one 
receptor, each receptor may respond to more than one chemokine and exert various effects, 
as well as each cell type expressing several different receptors (see Figure 2) (Kulbe, et al., 
2004). 
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Figure 3: Chemokine ligand and receptor interactions. Representation of known 
specific, shared, viral, or non-signaling chemokine receptors and the chemokines that bind 
with and activate them (Wilson and Slettenaar, 2006) 
 
 
1.4  GPCRs 
 G-protein-coupled receptors make up the vast majority of cell-surface receptors that 
are involved in signal transduction. They account for approximately 2% of the genes 
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encoded in the human genome (Dorsam and Gutkind, 2007). They all share a basic 
composition of seven-transmembrane α-helices that span across the plasma membrane 
(Dorsam and Gutkind, 2007). The G-proteins are associated with the cytoplasmic side of 
these receptors. They are composed of three basic subunits: Gα, Gβ and Gγ. When a 
signaling molecule, such as a chemokine, binds the extracellular N-terminal domain of the 
GPCR, the receptor interacts with the G-protein on the C-terminal, intracellular side and 
catalyzes the exchange of GDP for GTP in the Gα subunit. This causes the dissociation of 
the Gα from the bound Gβ/γ subunits. This allows both sets of subunits to go on and activate 
other intracellular molecules. This activation causes the Gα subunit to hydrolyze its GTP, 
producing GDP, which causes it to deactivate and reassociate with the Gβ/γ subunits. This 
heterotrimer then goes and reattaches to the heptahelical receptor and awaits another 
extracellular signal (Dhanasekaran, et al., 1998).  
 GPCR expression has been found in many different cells, including proliferating 
cells and contributing to cell growth and cancer, inflammation, neovascularization and 
tissue remodeling and repair (Dorsam and Gutkind, 2007). It has been observed that the 
normal physiological functions of GPCRs can by altered by malignant cells which leads to 
autonomous, uncontrolled proliferation, increased blood supply and invasion of other 
surrounding tissues and organs (Dorsam and Gutkind, 2007). Also, many GPCRs are 
overexpressed in several different cancer types, contributing to tumor cell growth. Since it 
has been found that several inflammatory mediators also stimulate GPCRs, this provides 
yet another possible link between inflammation and cancer (Dorsam and Gutkind, 2007). 
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1.5  CXCL8 
 Interleukin-8, more recently reclassified as CXCL8, was originally identified as a 
neutrophil chemotactic factor, meaning that it is an activator and chemoattractant for 
neutrophils (Xie, 2001). As its name implies, it is a member of the CXC chemokine family 
and also contains the glutamic acid-leucine-arginine motif making it an ELR+ CXC 
chemokine (Roebuck, 1999). The CXCL8 gene is located on human chromosome 4 in the 
q12-21 region. It contains four exons separated by three introns. When the CXCL8 gene is 
transcribed the product is a 1.8 kb mRNA that is then translated into a precursor protein 
that is 99 amino acids in length (Figure 4) (Roebuck, 1999). After intracellular processing 
the active protein that is secreted from the cell is only 79 amino acids long. Further 
extracellular processing of the secreted protein results in a few different biologically active 
forms, however it is the 72 amino acid form, with a molecular mass of 8.5 kD, that 
predominates (Roebuck, 1999). This extracellular processing can be performed by MMP-9 
(matrix metatalloproteinase-9 or gelatinase B) and has been found to actually increase 
CXCL8 activity by anywhere from 10 to 27 times (Van den Steen, et al., 2000).  
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Figure 4: Structure of CXCL8 gene and amino acid sequence. CXCL8 gene contains 
four exons and three introns of varying lengths with a TATA box at the 5’ end and 
polyadenylated tail at the 3’ end. The amino acid sequence is shown along with the signal 
peptide region as well as the conserved CXC sequence (Roebuck, 1999). 
 
 
 CXCL8 expression is most strongly stimulated by the proinflammatory cytokines 
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) (Brasier, et al., 1998). Other 
moderate activators of CXCL8 are stress factors such as nitrous oxide (Remick and 
Villarete, 1996), hypoxia and subsequent acidosis (Shi, et al., 1999). These factors rely on 
three basic transcription factors for CXCL8 expression: NF-κB, NF-IL-6 and AP-1 
(Nakamura, et al., 1991). For effective transcriptional responses in many cell types, it has 
been noticed that synergistic interactions among these three transcription factors need to 
take place (Mukaida, et al., 1994).  
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 As mentioned earlier, the first role identified for CXCL8 was as a chemoattractant 
cytokine for neutrophils during inflammation. Since then it has been implicated in several 
key roles in many human cancers. These include increased tumor cell proliferation, 
migration and angiogenesis (Yuan, et al., 2000; Li, et al., 2005; Li, et al., 2003; Zhu, et al., 
2004; Huang, et al., 2002; Itoh, et al., 2005; Opdenakker and Van Damme, 2004, Luppi, et 
al., 2006).  
It has been observed that CXCL8 can work in an autocrine and paracrine manner to 
increase tumor cell proliferation (Schadendorf, et al., 1993). Also, recent studies have 
shown that CXCL8 may stimulate proliferation through transactivation of epidermal 
growth factor receptors (EGFR) via G-protein activation and subsequent epidermal growth 
factor (EGF) shedding by matrix metalloproteinase (MMP) cleavage (Itoh, et al., 2005; 
Luppi, et al., 2006). Further proof of involvement with proliferation comes from CXCL8 
gene knockdown experiments, which showed that a decrease in CXCL8 expression leads 
to decreased tumor cell growth (Miyamoto, et al., 1998). Metastasis of tumor cells away 
from the primary site of growth has been shown to involve CXCL8. In order for migration 
of cells to occur the extracellular matrix surrounding tissues must be degraded. This is 
done in part by a group of enzymes known as matrix metalliproteinases (MMP). It was 
found that CXCL8 upregulates cellular expression of MMP-2 and MMP-9, which are both 
capable of degrading type-IV collagen, a major component of the basement membrane (Li, 
et al., 2003; Li, et al., 2005; Patel, et al., 2005; Handsley and Edwards, 2005). At the same 
time, as mentioned earlier, MMP-9 cleavage of CXCL8 creates a more active chemokine 
(Van den Steen, et al., 2000). From this information it would be safe to imply that a 
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positive feedback mechanism is created that would perpetuate tumor cell migration. All of 
these processes such as proliferation and migration, in which CXCL8 has been implicated, 
have high metabolic demands (Strieter, et al., 2005). Tumor cells (and non-tumor cells) use 
several different strategies to accomplish this. Several findings have implicated CXCL8 as 
playing a role in increasing tumor angiogenesis. The processes used in order to accomplish 
this include the chemoattraction of endothelial cells by CXCL8. This increasing gradient of 
CXCL8 as proximity to tumor cell mass decreases causes the endothelial cells to increase 
their MMP-2 and MMP-9 expression which helps to pave the way by breaking down the 
extracellular matrix surrounding the tissues (Dorsam and Gutkind, 2007). Several studies 
have confirmed the increased expression of CXCL8 in tumor cell masses that show 
increased angiogenesis, as well as the concomitant increases in MMP production (Huang, 
et al., 2002; Yuan, et al., 2000; Li, et al., 2003; Li, et al., 2005). 
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Figure 5: Expression and function of IL-8 in tumor growth. Diagram depicts a 
few factors that lead to increased IL-8 production and the subsequent effects it 
plays in tumor cell proliferation, metastasis and angiogenesis (Xie, 2001).  
 
1.6  CXCL8 Receptors 
 As mentioned earlier, almost all chemokines are coupled to at least one seven 
transmembrane G-protein coupled receptor, this is true for CXCL8 as well. The two 
CXCL8 chemokine receptors are CXCR1 and CXCR2 (Bizzarri, et al., 2006; Richards, et 
al., 1997; Strieter, et al., 2005). The CXCR1 receptor is more specific in its ligand binding 
and has been found to only interact with CXCL6 and CXCL8 with high affinity (Holmes, 
et al., 1991). On the other hand, the CXCR2 receptor has been found to be more 
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promiscuous in its interactions and can bind all ELR+ CXC chemokines, which include: 
CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 and CXCL15 (Addison, et 
al., 2000). These two receptors are associated with different aspects of CXCL8 induced 
changes in tumor cells. Although there is a lot of controversy as to the specific roles that 
each plays, it seems that several conclusions can be made. The first involves angiogenesis. 
Since it has been found that all ELR+ CXC chemokines are pro-angiogenic (a function of 
the ELR motif), and all ELR+ CXC chemokine ligands bind to CXCR2, it can be deduced 
that CXCR2 is involved in the pro-angiogenic effect of CXCL8. This conclusion has been 
supported by several different research groups (Strieter, et al., 2005; Addison, et al., 2000; 
Heidemann, et al., 2003; Varney, et al., 2006). The proliferative effects of CXCL8 have 
also been associated with ligand interactions with the CXCR2 receptor (Addison, et al., 
2000; Wuyts, et al., 1998; Schraufstatter, et al., 2000). The function of CXCR1 has not 
been as well defined but seems as if it may be involved with the chemoattractant properties 
of CXCL8 for neutrophils (Hammond, et al., 1995; Bertini, et al., 2004).  
 
 
1.7  CXCL8 and HNSCC 
 In the current study, the effects of CXCL8 on head and neck squamous cell 
carcinoma were examined. Based on previous studies of CXCL8, we hypothesized that the 
overexpression of CXCL8 in head and neck squamous cell carcinoma causes an increase in 
proliferation and motility in HN4 and HN12 cells. This was examined using two different 
approaches: overexpressing CXCL8 in cells that express low endogenous levels of this 
16 
chemokine, and RNAi-mediated knockdown in cells expressing elevated endogenous 
levels of CXCL8. The overexpression of CXCL8 was performed in HN4 cells, which were 
derived from a primary squamous cell carcinoma of the tongue (Yeudall, et al., 2005; 
Miyazaki, et al., 2006). It was found that HN12 cells overexpressed CXCL8 (Miyazaki, et 
al., 2006) and for this reason the knockdown experiments were performed in HN12 cells, 
which were derived from a nodal metastasis in the same patient that the HN4 cell line came 
from (Yeudall, et al., 2005; Miyazaki, et al., 2006).  
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Materials and Methods 
 
2.1  Cell Cultures 
 
 HN12 and HN4 cell lines were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) (4500 mg/L D-Glucose, L-Glutamine and 110 mg/L sodium pyruvate) 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and 1mL 
penicillin/streptomycin (10,000 u/mL penicillin, 10,000µg/mL streptomycin sulfate in 
0.85% saline) (Invitrogen, Carlsbad, CA) for 293-T cells, in the presence of puromycin (1 
µg/ml) for transfected HN12 cells or in the presence of G418 (400µg/ml) for HN4 cells. 
They were maintained in a humidified, 37º C incubator in 90% air and 10% CO2. 
 
2.2  Oligonucleotide Synthesis 
 The RNA sequence that was targeted in order to knock down expression of CXCL8 
was identified using online software (www.clontech.com,  2007) and appropriate 
oligonucleotides designed (see Table 1). Oligonucleotides containing 5’ phosphorylations 
were synthesized by Sigma-Genosys, (The Woodlands, TX) and were designed with 
BamHI and EcoRI compatible ends for ligation into a plasmid (see Table 1 for primer 
sequences).  
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2.3  Polymerase Chain Reaction 
 
 Reagents were thawed and set up as a 50 µL reaction mix in a 200 µL tube as 
follows: 40 µM dNTP mix, 10x PCR Buffer (200 mM Tris HCL pH 8.4 and 500 mM 
KCl)(Promega, Madison, WI), 10 µM Primers, 0.5 µg template DNA, 0.5 µL Taq DNA 
Polymerase (Promega, Madison, WI) and ddH2O was add up to a total volume of 50 µL. 
The tube was briefly spun down and placed in the GeneAmp PCR System 9700 (40 cycles 
95º C for 30 sec and 68ºC for 1.2 min)(Applied Biosystems, Foster City, CA).  
 
2.4  Restriction Endonuclease Digestion 
 
 In order for the CXCL8 or shL8 sequences to be introduced into the plasmid of 
choice, restriction endonuclease digestions were performed. The pSirenRetroQ plasmid 
vector (Clontech) was digested with BamHI  and EcoRI (New England Biolabs, Ipswich, 
MA) and the pcDNA3 plasmid vector was digested with BamHI (New England Biolabs, 
Ipswich, MA) and XbaI (Promega, Madison, WI) by addition of 20 u/µL of each enzyme, 
10x BSA, 10x NEBuffer #2 (10mM Tris HCl, 10mM MgCl2, 50mM NaCl, 1mM 
Dithiothreitol pH 7.9) (New England Biolabs, Ipswich, MA), 200 ng pSirenRetroQ 
plasmid and 6 µL ddH2O. The solution was allowed to incubate in a 37º C water bath for at 
least 1h.  
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2.5  DNA Ligation 
 
 To a sterilized microcentrifuge tube the following were added: 1:3 molar ratio of 
oligonucleotide:vector, 4µl of 5x T4 DNA Ligase Buffer (250 mM Tris-HCl pH 7.6, 50 
mM MgCl2, 5 mM ATP, 5 mM DTT and 25% (w/v) polyethylene glycol-8000), ddH2O to 
19.5 µL and 0.5 µL T4 DNA Ligase (Invitrogen, Carlsbad, CA). Finally, the solution was 
incubated at room temperature for 2 h.  
 
2.6  Agarose Gel Electrophoresis 
 
 A 1% agarose gel was prepared using 0.5 mg Agarose (ISC BioExpress, Kaysville, 
UT) in 50 mL 1x TAE buffer. The products were mixed with 6x DNA running buffer and 
run on the gel for 15-30 min at 120V side by side with a 1 kb Molecular Ruler (BioRad, 
Hercules, CA) 
 After the contents of the digestion were run on a 1% agarose gel the QIAquick Gel 
Extraction Kit (QIAGEN Sciences, MD) was used purify the digested plasmid DNA 
according to the manufacturer’s protocol. First, the DNA fragment was excised from the 
gel using a clean, sharp scalpel. The slice was placed in a microcentrifuge tube with 300 
µL Buffer QG. It was then incubated at 50º C for 10 min until the gel slice had completely 
dissolved. Vortexing every 2 min helped this process. Once completely dissolved, 100 µL 
of isopropanol was added and the entire solution was added to the QIAquick spin column 
in a 2 mL collection tube. The tubes were spun at top speed for 1 min in a microcentrifuge. 
The flow-through was discarded and 750 µL of Buffer PE was added to the column to 
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wash by centrifugation for another minute. The flow through was again discarded and the 
column spun again for 1 min at 13,000 rpm. The QIAquick column was placed in a clean 
1.5 mL microcentrifuge tube and 50 µL of ddH2O were added. The column was incubated 
at ambient temperature for 1 min and then centrifuged at top speed for 1 min to collect the 
eluted DNA.  
 
2.7  Spectrophotometric Calculation of Nucleic Acid Concentration  
 
 Estimation of nucleic acid concentration was carried out in a DU 640 
Spectrophotometer (Beckman Coulter, Fullerton, CA). The spectrophotometer was blanked 
at 260 nm and 280 nm using 50 µL of ddH2O, then 50 µL of diluted sample (1:20 in 
ddH2O) was placed in the spectrophotometer and the absorbances at 260 and 280 nm were 
read. Concentration of double-stranded DNA or single-stranded RNA is calculated by the 
following equations: 
DNA:  1OD @ 260 nm = 50 ng/µL 
RNA:  1OD @ 260 nm = 34 ng/µL 
 
 
2.8  E. coli Transformation 
 
 Cells were removed from –80º C storage and thawed on wet ice. 2 µg of DNA 
solution were added to 50 µL of α-Select chemically competent cells (Bioline, Randolph, 
MA) and solution was gently swirled for a few seconds to mix. It was then incubated on 
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ice for 30 min at which time the tube was placed in a 42º C water bath for  45 s and then 
returned to ice for 2 min. The transformation reaction was then diluted by addition of 250 
µL of SOC medium (2% tryptone, 0.5% yeast extract, 0.4% glucose, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2 and 10 mM MgSO4) (Bioline, Randolph, MA). The tubes were 
placed in a 37º C incubator and shaken at 200 rpm for 60 min. The cells were then plated 
by addition of 20 µL of cell transformation mixture on LB agar plates containing 50 
µg/mL ampicillin and incubated overnight at 37º C.  
 
 
2.9  Small Scale DNA Preparation 
 
 Miniprep DNA was purified using the Wizard Plus SV Miniprep DNA Purification 
System (Promega, Madison, WI). After E. coli colonies were picked and expanded in 
liquid culture, 1.5 mL of the resuspended solution was pelleted by centrifugation for 5 min. 
After drawing off the supernatant, the cells were thoroughly resuspended with 250 µL of 
Cell Resuspension Solution (50mM Tris-HCl pH 7.5, 10mM EDTA, 100µg/mL RNase A) 
(Promega, Madison, WI) and incubated at room temperature for 3-4 minutes. Next, 250 µL 
of Cell Lysis Solution (0.2M NaOH, 1% SDS) (Promega, Madison, WI) was added to each 
sample and inverted 4 times to mix. Samples were then incubated at ambient temperature 
for 4 min. 10 µL of Alkaline Protease Solution was added to each sample, inverted 4 times 
to mix and incubated at ambient temperature for 5 min. 350 µL Neutralization Solution 
(4.09M guanidine hydrochloride, 0.759M potassium acetate, 2.12M glacial acetic acid) 
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(Promega, Madison, WI) was then added to the solution, inverted 4 times to mix and 
centrifuged at 13,300 rpm for 10 min. Spin column (Promega, Madison, WI) was inserted 
into a vacuum adapter and the clear lysate added. A vacuum was applied until all the liquid 
had passed through. 750 µL of Wash Solution with ethanol (Promega, Madison, WI) was 
added and vacuum was again applied until all the solution passed through. This step was 
repeated again with 250 µL of Wash Solution (Promega, Madison, WI). The column was 
then dried by applying vacuum for 10 min. Next, the column was transferred to a 2 mL 
collection tube and centrifuged at 13,300 rpm for 2 minutes. The column was again 
transferred to a sterile 1.5 mL microcentrifuge tube and 100 µL of ddH2O was added. It 
was then spun at top speed for 1 min to elute the DNA. The DNA was then ready to be 
stored at –20º C.  
 
2.10  Cell Transfection 
 
10 cm cell culture plates were plated with 293-T, HN4 or HN12 cells and were 
grown to 60% confluency. In a sterile microcentrifuge tube 10 µL/µg DNA of the TransIT- 
Keratinocyte Transfection Reagent (Mirus, Madison, WI) was added dropwise into 200 µL 
of serum-free media and was mixed thoroughly by vortexing. This was then incubated at 
ambient temperature for 20 min. DNA (2 µg) was then added to the diluted TransIT- 
Keratinocyte Transfection Reagent (Mirus, Madison, WI) and mixed by gentle pipetting. 
After a 20 min incubation, the transfection mix was added to the prepared cultures and 
gently rocked side to side to distribute the reagent/DNA mixture evenly.  
23 
 
2.11  RNA Extraction 
 
 Cells were lysed directly in the culture dish by addition of 1 mL of TRIsure 
(Bioline, Randolph, MA) per 10 cm2 growth area. The plates were incubated at ambient 
temperature for 5-10 minutes and then scraped with a cell scraper and contents 
resuspended and transferred to a 1.5 mL microcentrifuge tube. 0.2 mL of chloroform per 1 
mL of Trisure used was added, tubes were capped and shaken vigorously for 15 s. Samples 
were then incubated for 2-3 min at ambient temperature and then centrifuged at 12,000 x g 
for 15 min at 4º C. The upper aqueous phase was transferred to another tube and mixed 
with 0.5 mL isopropyl alcohol per 1 mL TRIsure used. The samples were then incubated at 
ambient temperature for 10 min and then centrifuged at 12,000 x g for 10 min at 4ºC. The 
supernatant was then removed and the pellet washed using 75% ethanol, adding at least 1 
mL ethanol per 1 mL Trisure used. Samples were then vortexed and centrifuged at 7,500 x 
g for 5 min at 4º C. The supernatant was again removed and the pellet was allowed to air 
dry at ambient temperature for 5-10 min. The RNA was then dissolved in 20 µL of RNase-
free H2O and stored at –80º C.  
 
2.12  Reverse Transcription 
 
 A mix was prepared containing 1 µg total RNA, 1 µL oligo(dT)18 primer and 
ddH2O up to 12 µL total. The mix was incubated for 5 min at 70º C, and then chilled on 
ice, after which 1 µL 40 mM dNTP mix (10 mM each), 4 µL 5x reaction buffer (2M Tris-
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HCl pH 8.0, 5M NaCl, 0.5 EDTA) (Bioline, Randolph, MA) and ddH2O up to 19.75 µL 
total were added to the mixture. This was then mixed by gently pipetting. Next, 0.25 µL of 
BioScript reverse transcriptase (200 u/µL; Bioline, Randolph, MA) was added and the 
solution was incubated at 37º C for 60 min. The reaction was then stopped by heating at 
70º C for 10 min and stored at –20º C.  
 
 
2.13  Quantitative Polymerase Chain Reaction (qPCR) 
A master mix containing 5% 45µg (1/10x diluted) primers (see Table 1), 35% 
ddH2O and 50% ABsolute SYBR Green ROX Mix (ABgene, Epsom, Surrey, UK) was 
made for each gene target to be analyzed. Actin primers were used as housekeeping genes 
to standardize the amount of cDNA initially added to each sample (see Table 1 for list of 
primer sequences). After 9 µL of the master mixes were added to the wells of a 96-well 
optical plate (Applied Biosystems, Foster City, CA) 1µL ddH2O was added to the non-
template controls, 1 µL of diluted amounts of known templates were added to additional 
wells to act as standards, which allowed relative standard curves to be constructed from 
which relative cDNA copy number could be determined. For test (unknown) samples, 1 µL 
of desired cDNA was added to triplicate wells. The 96-well plate was covered with an 
optical cover and then inserted into the 7500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA) and the run initiated using the 7500 Fast System SDS 
Software (Applied Biosystems, Foster City, CA).  
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Table 1. Primer Sequences 
Primer name Sequence 
shL8- sense 5’GATCCGTCCTGATTTCTGCAGCTCTTTCAAGAGA 
AGAGCTGCAGAAATCAGGATTTTTTACGCGTG-3’ 
shL8- antisense 5’AATTCAGCGTAAAAAATCCTGATTTCTGCAGCTC 
TTCTCTTGAAAGAGCTGCAGAAATCAGGACG-3’ 
CXCL8- sense 5’-TTTTGCCAAGGAGTGCTAAAG-3’ 
CXCL8- antisense 5’-AACCCTCTGCACCCAGTTTTC-3’ 
Actin- sense 5’-CATGTACGTTGCTATCCAGGC-3’ 
Actin- antisense 5’-CTCCTTAATGTCACGCACGAT-3’ 
 
 
 
2.14  Conditioned Media 
 
 Cells were washed with PBS, removed from the plate using 0.1% Trypsin EDTA 
(Greiner Bio-One, Monroe, NC) and counted. The cells were then replated ensuring equal 
numbers of cells in all plates. After 24 h the cells were washed twice with PBS and 10 mL 
DMEM/1% BSA (Invitrogen, Carlsbad, CA) was added and cells were returned to the 37º 
C incubator for 48 h. At that time the media were removed, aliquoted into microcentrifuge 
tubes and stored at –20º C.  
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2.15  Immunoprecipitation 
 
 Mouse anti-human IL-8 monoclonal antibody (1 µg per 1 mg of protein) 
(GenScript Corp., Piscataway, NJ) was added to 1 mL of conditioned media and incubated 
for 24-48 h at 4º C with end-over-end rotation. Then 30 µL of 50% Gammabind G 
Sepharose (Pharmacia Biotech AB, Uppsala, Sweden) in PBS was added to each sample 
and incubated for a further 1 h at 4º C with rotation. Samples were then centrifuged at 
10,000 rpm for 5 min at 4º C. The supernatant was then decanted and 1 mL of PBS was 
added. The tube was gently flicked to resuspend and wash the pellet and then recentrifuged 
for 1 min. This step was repeated twice. After the final wash, the tube was recentrifuged 
without addition of buffer and a micropipette was used to remove all the remaining 
supernatant. The sepharose-antibody-protein complexes were resuspended in 1x SDS-
PAGE loading buffer, heated to 95º C for 10 min, then either run on a polyacrylamide gel 
or stored at –20º C.  
 
2.16  Western Blot 
 
 Immunoprecipitated proteins, or concentrated conditioned media samples, were 
resolved in 15% denaturing polyacrylamide gels containing 0.1%  SDS (Molecular 
Cloning: A Laboratory Manual 2001). Proteins were resolved for 1.5 h at 120 V in 1x 
SDS-PAGE running buffer (20 mM Tris-Cl (pH 7.9), 100 mM NaCl, 70 mM EDTA, 2% 
(w/v) SDS). Next, proteins were transferred onto PVDF membrane (Immobilon-P; 
Millipore Corp., Bedford, MA) for 16h in 1x transfer buffer (20 mM Tris-HCl (pH 7.9), 
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100 mM NaCl, 70 mM EDTA, 20% MeOH). The membrane was  dried, rehydrated, then 
blocked with 5% non-fat dried milk in 0.05% tween-TBS (T-TBS) for 1 h on a shaker at 
ambient temperature. After three 5 min washes in T-TBS the membrane was incubated in a 
1:1000 (1µg/mL) mouse anti-human IL-8 monoclonal antibody (GenScript Corp., 
Piscataway, NJ) diluted in 1% BSA (EMD Chemicals Inc., Gibbstown, NJ) overnight at 
4°C. After three 5 min T-TBS washes the membrane was incubated in horseradish 
peroxidase-conjugated (HRP) goat anti-mouse monoclonal antibody diluted 1:1000 in 
blocking buffer for 1 h on a shaker at ambient temperature. The interaction of the primary 
and secondary antibodies was detected using Western Lightning Chemiluminescence 
Reagent Plus (PerkinElmer Life Sciences Inc., Boston, MA) 
 
2.17  MTT Assay 
 
 To determine proliferation, cells were trypsinized using 0.1% trypsin-2.21 mM 
EDTA (Mediatech, Herndon, VA) and counted. The cells were replated in triplicate in 12-
well cell culture plates (Greiner Bio-One, Monroe, NC) at a density of 1x104 cells per well. 
The cells were incubated for 5 days (HN12) or 7 days (HN4). At that time 100 µL of MTT 
Solution (3-(4,5-Dimethylthiazolyl-2)-2,5-Diphenyl Tetrazolium Bromide) (MP 
Biomedicals Inc., Solon, OH) was added to each well and incubated at 37° C for 4 h. Next, 
all media and MTT solution was removed from each well and 1 mL of MTT solubilization 
solution (10% SDS in 0.01M HCl) was added and incubated overnight at 37° C. After all 
crystals had been dissolved the optical density of the solution was determined 
spectrophotomettically at 570 nm. 
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 Alternatively, 1x104 HN12 cells or 2x104 HN4 cells, or derivative cell lines were 
plated in triplicate in eight 12-well cell culture plates. On each of 8 consecutive days, 1 
plate was removed, 100 µL of MTT solution added to the media and incubated at 37° C for 
4 h. At this point media were removed completely and the plates were stored at -80° C 
until all 8 plates had been collected. Crystals were solubilized and the optical density 
determined as before.  
 
2.18  Migration Assay 
 
 Cells were detached from culture plates in 1-2 mL of HBSS/5 mM EDTA/25 mM 
Hepes pH 7.2 (+/- 0.01% trypsin) (Mediatech, Herndon, VA). Cells were then washed 
twice in DMEM/0.1% BSA (Invitrogen, Carlsbad, CA) and resuspended at a density of 
2.5x105/mL. 200µL of the cell suspension was added to the upper chamber of an 8.0µm 
pore size Transwell insert (Corning Inc, Corning, NY) in triplicate. 1 mL of serum-free 
DMEM/0.1% BSA/10 ng/mL EGF was added to the lower chamber of each well . The 
cells were placed in a 37º C incubator for 20 h and allowed to migrate. The plate was then 
removed from the incubator and the cells were fixed with 0.025% glutaraldehyde (Sigma-
Aldrich, St. Louis, MO) in PBS. The membranes were then stained with 0.1% crystal 
violet in PBS for a minmimum of 20 min, then destained thoroughly with ddH2O. The non-
migratory cells on the upper surface of the membrane were removed by wiping with a Q-
tip and the membranes were mounted on a glass microscope slide. Cells were counted in 5 
random fields per membrane at 200x magnification.  
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Figure 6:  Migration Assay. Representation of an individual cell culture well used for the 
migration assays performed. Cells were plated on top portion of porous membrane and 
media supplemented with EGF was placed in the bottom chamber. 
 
 
2.19  Invasion Assay 
 
 Invasion assays were carried out in a similar manner to migration assays. Transwell 
inserts with 12.0 µm pores (Corning Inc., Corning, NY) were coated with 200 µL Matrigel, 
which was diluted 1:6 in ice-cold DMEM, and allowed to gel at 37º C for 20-30 min. 
Subconfluent cell cultures were then washed with PBS and incubated at 37º C in 1-2 mL 
HBSS/5 mM EDTA/25 mM Hepes pH 7.2 (Mediatech, Herndon, VA) until detached. They 
were then resuspended in DMEM/0.1% BSA at a density of 2x105 cells/2 mL. 1 mL of 
DMEM/0.1% BSA/10 ng per mL EGF was added to the lower chamber of each well; the 
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Transwells were placed in each well ensuring that no bubbles formed below the membrane, 
and 500 µL of cell suspension (5x104 cells) were added to the upper chamber. The plates 
were then incubated in a 37º C incubator for 16-20 h, after which the plates were removed 
from the incubator and cells fixed, stained and counted as for migration assays (above).  
 
 
Figure 7:  Invasion Assay. Representation of the setup used for the invasion assays. A 
porous membrane is first covered with Matrigel, placed in the chamber, cells of choice are 
plated on top of the membrane and media supplemented with EGF was placed in the 
bottom chamber.  
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2.20  Statistical Analysis 
 
 All data was analyzed using an unpaired t-test comparing two means using 
GraphPad QuickCalcs software (http://www.graphpad.com/quickcalcs/). All p-values were 
compared to an α-value of either 0.05 or 0.005.
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Results 
 
3.1  Targeted Suppression of CXCL8 Expression 
 
 It has been previously reported that the HN12 cell line, which was derived from a 
nodal metastasis in a patient with head and neck squamous cell carcinoma, overexpressed 
CXCL8 approximately 2 fold when compared to HN4 cells, which were derived from the 
primary tumor in the same patient as the HN12 cells (Miyazaki 2006). In order to study the 
biological role of CXCL8 in HN12 cells we used RNA interference (RNAi) to specifically 
inhibit the expression of CXCL8. This was done by stably transfecting HN12 cells with a 
pSiren-RetroQ plasmid that synthesizes shRNA targeted to degrade CXCL8 mRNA, or a 
non-targeting control (NTC) plasmid. Individual clones (HN12-shL8, HN12-NTC) were 
selected for resistance to puromycin and screened for CXCL8 expression by extracting 
RNA, reverse transcription and subsequent analysis by qPCR using cDNA as a template. 
In addition, conditioned media were collected and levels of secreted CXCL8 determined 
by immunoprecipitation and western blot analysis as described in Materials and Methods. 
As shown in Figure 8 (top panel) CXCL8 expression was decreased 2.5 fold when 
compared to the control, as judged by qPCR. This was a significant difference having a p-
value of 0.002. Western blot analysis (lower panel) confirmed a decrease of CXCL8 in the 
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shL8 cells. Thus, stable targeted suppression of CXCL8 expression was achieved in HN12 
cells. 
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Figure 8:  RNA was extracted from subconfluent cultures of the indicated cells, reverse-
transcribed and qPCR as performed as described in Materials and Methods. The expression 
of CXCL8 was standardized to the internal standard, actin (top panel). The assay was 
performed in triplicate and relative means ± 1 SEM are shown. In parallel, equal numbers 
of HN12-NTC and HN12-shL8 cells were serum deprived for 48 h and conditioned media 
collected. CXCL8 was immunoprecipitated and western blotted with anti-CXCL8 
antibody. (** represents p<0.005) 
CXCL8 
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3.2  Overexpression of CXCL8 
 HN4 cells express low basal levels of CXCL8 and, thus, are a good target cell in 
which to test the effects of CXCL8 overexpression. To facilitate this, a full-length CXCL8 
cDNA was generated by PCR using HN12 cDNA as a template. CXCL8 cDNA was 
obtained and the CXCL8 sequence was restriction digested using BamHI and Xba1 and 
then ligated into the pcDNA3 plasmid, similarly digested. Recombinant clones were 
obtained and the presence of an insert of the predicted size was determined by restriction 
digestion. To further confirm the identity and integrity of PCR-generated sequences, 
individual clones were subjected to nucleotide sequence determination. To confirm that 
CXCL8 was expressible from these plasmids, 293T cells were used as a preliminary test 
due to this cell line’s high transfectability and ability to express a large amount of protein. 
293T cells were transiently transfected with pcDNA3-CXCL8 or pcDNA empty vector as 
control. Forty-eight hours later, RNA was prepared, reverse-transcribed and CXCL8 
expression determined by qPCR. As shown in Fig. 9(top panel) CXCL8 was almost 
undetectable in vector-transfected cells, but highly expressed in cells transfected with 
pcDNA-CXCL8. These data were found to be extremely statistically significant (p= 
0.001). Western blot analysis (Fig. 9, lower panel) confirmed these findings, with a similar 
trend in CXCL8 expression between the control and CXCL8-transfected cells. 
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Figure 9:  RNA was extracted from subconfluent cultures of 293T cells, reverse-
transcribed qPCR analysis was performed as described earlier in Materials and Methods. 
CXCL8 expression was standardized to the internal standard, actin (top panel). The assay 
was performed in triplicate for both controls and both CXCL8-transfected cells and relative 
means ± 1 sem are shown. In parallel, equal numbers of 293T cells, similarly transfected, 
were allowed to condition the media for 48h, and CXCL8 immunoprecipitated and 
expression determined by western blotting (lower panel)   
(** represents p<0.005) 
CXCL8
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After the ability of pcDNA3-CXCL8 plasmids to express CXCL8 was confirmed, a 
stable transfection was performed in HN4 cells. Individual clones were selected in G418 
and, again, CXCL8 expression levels were analyzed by qPCR after RNA extraction and 
reverse transcription. Figure 10 shows CXCL8 qPCR results obtained for HN4 cells. A 2-
fold difference between the control and CXCL8 overexpressing clone was observed. This 
difference was found to be significant ( p= 0.001). As before, conditioned media were also 
tested for CXCL8 expression by immunoprecipitation and western blotting. However, the 
levels of CXCL8 in these cells lines were not readily detectable by this methodology (data 
not shown). 
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Figure 10:  RNA was extracted from subconfluent cultures of the indicated cells, reverse-
transcribed and qPCR analysis performed as described earlier in Materials and Methods.  
CXCL8 expression was standardized to the internal standard, tubulin (top panel). The 
assay was performed in triplicate and relative means ± 1 SEM are shown. (** represents 
p<0.005) 
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3.3  CXCL8 overexpression leads to increased cellular proliferation 
 Increased cellular proliferation plays an integral role in tumor progression. To 
better understand the role that CXCL8 plays in this critical process we used the HN12-
NTC and HN12-shL8 cells, as well as the HN4-NTC and HN4-CXCL8 cell lines described 
above. Equal numbers of cells were plated in triplicate (1x104 per well for HN12 and 2x104 
per well for HN4) in 12-well cell culture plates, and cultured for 5 or 8 days (HN12 and 
HN4, respectively) and then subjected to MTT Assay. This allowed us to observe a final 
difference in proliferation between the control and experimental groups of both cell lines. 
As shown in Fig. 11A, a 3-fold decrease in the proliferation of HN12-shL8 cells was 
observed when compared to the control. These data were statistically significant (p=0.022). 
Similarly, overexpression of CXCL8 in HN4 cells (Fig. 11B) resulted in an increase in 
proliferation of 2-fold compared to controls. Again, this is statistically significant (p= 
0.003). 
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Figure 11:  Equal numbers of the indicated cells were plated in triplicate and incubated 
under standard culture conditions. MTT assay was carried out after 5 days (A) or after 8 
days (B) as described in Materials and Methods. Values shown are means ± SEM.        (** 
represents p<0.005) 
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 This difference in proliferation was further confirmed by daily cell counting, as 
well as by daily MTT assay.  Figure 12A shows the results of HN12-NTC and HN12-shL8 
proliferation assay where the cells were counted for eight consecutive days. The same 
general trend was observed, with HN12-shL8 cells showing less proliferation. As can be 
seen from Fig.12B, there is a statistically significant difference between the cell numbers 
of the HN12-shL8 cells compared to control, with the eight day showing around a 50% 
decrease in proliferation. Similarly, figure 12C shows a similar trend for HN4-CXCL8 
compared to control cells. At almost all timepoints a significant increase in proliferation 
between the HN4-CXCL8 cells was observed compared to control, with the eighth day 
showing an 2-fold increase in growth. 
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Figure 12:  Equal numbers of the indicated cells were plated in triplicate and incubated 
under standard culture conditions. (A) Cells were trypsinized and counted daily for eight 
consecutive days. (B&C). MTT assay was carried out as described in Methods. Values 
shown are means of cell number ± 1 SEM. (* represents p<0.05 and ** represents 
p<0.005) 
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3.4  CXCL8 Stimulates Cell Migration and Invasion 
 Along with increased proliferation, CXCL8 has been implicated in increasing 
cellular migration, and might, potentially, affect invasion into other tissues leading to 
metastasis of the tumor. To test this, both the HN12-NTC and HN12-shL8 cells, as well as 
the HN4-NTC and HN4-CXCL8 cells were used. Equal numbers of cells were plated in 
triplicate in the upper chamber of a Transwell cell culture plate as described in Materials 
and Methods. In the bottom chamber, cell culture media containing EGF, which acts as a 
chemoattractant, was added and cells incubated under standard conditions for 16-20 h, 
after which migratory cells were stained and counted. Figure 13A shows approximately a 3 
fold decrease in migration in the HN12-shL8 cells when compared to the control. These 
data were statistically significant with a p-value of 0.001. Similarly, Figure 13B shows the 
same trend in HN4 cells. The HN4-CXCL8 cells showed a 3-fold increase in migration 
when compared to the control. These data are also statistically significant (p=0.006). These 
results support the hypothesis that CXCL8 leads to increased cell migration.  
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Figure 13:  The indicated cells were detached from culture plates in the absence of trypsin, 
washed and plated in upper chamber of Transwell inserts as described in Materials and 
Methods. After 16 h (A) or 20 h (B), migrated cells were stained and counted in 15 random 
high power fields. Data shown represent mean ± SEM. (** represents p<0.005). 
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HN12 cells are highly invasive in vitro (Li, et al., 2003; Zhu, et al., 2004). To test 
the hypothesis that CXCL8 leads to increased invasion, the HN12-NTC and HN12-shL8 
cells were plated in triplicate on the upper chamber of Matrigel-coated Transwells and 
allowed to migrate. After 16 h invading cells were stained and counted. Figure 14 shows 
the data obtained from a representative experiment. A clear difference between the HN12-
shL8 and control cells is apparent, with a statistically significant 3-fold decrease in 
invasion observed for the HN12-shL8 cells (p= 0.001). These data indicate that CXCL8 
contributes to the invasive phenotype of HN12 cells. 
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Figure 14:  HN12-shL8 and HN12-NTC cells were plated in Matrigel-coated Transwell 
chambers as described in Materials and Methods. 16 h later, invading cells were stained 
and counted in 15 random high power fields. Data shown represent mean ± SEM. (** 
represents p<0.005) 
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Discussion 
 
4.1  Current Study 
 
 The aims of the current study were to determine what role CXCL8 plays in the 
proliferative and metastatic characteristics of primary (HN4) and metastatic (HN12)  
HNSCC cells. Previous reports in other cell lines lead to testing the hypothesis that 
increased levels of CXCL8 leads to increased cellular proliferation as well as an increased 
ability of the cells to migrate and invade into other nearby tissues. 
 
4.2  HNSCC Model 
 In order to study the effects of CXCL8 on HNSCC cells an in vitro approach was 
taken. Previously, HNSCC cell lines had been isolated and maintained in culture. The first 
of these cell lines was the HN4 cell line, which was generated from the primary tumor of 
the tongue. The second cell line was the HN12 cell line, which was isolated from a lymph 
node metastasis in the same patient from which the HN4 cells were obtained (Miyazaki, et 
al., 2006; Yeudall, et al., 2005). To find out what differences did exist in the two cell lines 
a microarray analysis was performed (Miyazaki, et al., 2006), which showed that 
approximately 60 genes total were either overexpressed or downregulated in the HN12 
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cells when compared to the HN4 cells. More specifically, two genes that were found to be 
upregulated were the CXC chemokines CXCL5 and CXCL8. Proliferation and 
migration/invasion assays were previously performed on both cells lines while genetically 
modifying CXCL5 levels and it was reported that increased levels of CXCL5 lead to 
increased proliferation and metastatic ability of cells (Miyazaki, et al., 2006). The 
previously mentioned microarray study showed that CXCL8 was increased over 2 fold in 
HN12 cells when compared to HN4 cells. This data along with previous reports of the role 
of CXCL8 in various cancers lead to the idea that CXCL8 may play a prevalent role in 
HNSCC progression, and is the basis for the current study.  
 In order to test the role of CXCL8 in HNSCC using the HN4 and HN12 cells, two 
approaches were taken. In the first approach, HN12 cells, which were found to overexpress 
CXCL8, were subjected to RNA interference, which allows the knockdown of the CXCL8 
gene. The second approach used was by overexpressing CXCL8 in HN4 cells, which have 
a baseline level of the protein. However, before this second approach was taken with the 
HN4 cells, 293T cells, which are good at expressing large amounts of protein, were used 
for a transient transfection in order to ensure that CXCL8 could be overexpressed in HN4 
cells. 
 After genetic modification, the expression levels of CXCL8 in HN12 cells was 
confirmed using both qPCR and western blot analysis. Both sets of experiments showed 
similar knockdown trends for CXCL8, with about a 2.5 fold decrease in the HN12-shL8 
knockdown when compared to the control. In the transient transfection with 293T cells, the 
qPCR and western blot results show that overexpression of the protein is possible with 
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qPCR results showing a 260 and 615 fold increase in two separate test lines. Once HN4 
cells were stably transfected the expression levels were tested using qPCR only. These 
results showed approximately a 2-fold increase in the HN4-CXCL8 overexpressing cell 
line when compared to the control. Western blot analysis of this cell line could not detect 
the presence of CXCL8, even with the various concentrations of primary antibody used to 
probe the transfer membrane. This lead us to believe that the since the baseline levels of 
CXCL8 are low in this cell line, even the overexpression of the protein would not cause the 
increase to be of detectable levels using our methods. 
 
4.3  CXCL8 Expression and Proliferation 
 Several studies have been done which link CXCL8 to increased tumor growth and 
proliferation (Yuan, et al., 2000; Li, et al., 2005; Li, et al., 2003; Zhu, et al., 2004; Huang, 
et al., 2002; Itoh, et al., 2005; Opdenakker and Van Damme, 2004, Luppi, et al., 2006). 
More specifically it is believed to function via an autocrine and paracrine mechanism 
(Schadendorf, et al., 1993). Results from the current study have confirmed these results in 
both HN12 and HN4 tumor cell lines. In the HN12 line, when comparing the HN12-shL8 
knockdown to the control there was significantly decreased cellular proliferation. 
Similarly, in the HN4 cell line, the HN4-CXCL8 overexpressing cells lead to a significant 
increase in cellular proliferation when compared to the control. 
 Although some of the results may be debatable, it seems as though the predominant 
CXCL8 receptor that is responsible for its proliferative effects on cells is the CXCR2 
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receptor and to a lesser extend CXCR1(Addison, et al., 2000; Wuyts, et al., 1998, 
Schraufstatter, et al., 2000; Hammond, et al., 1995; Bertini, et al., 2004). Both of these 
receptors are coupled to G-proteins and have many downstream proteins that they interact 
with upon ligand binding and activation. One possible mechanism responsible for the 
increased proliferation associated with CXCL8 is the interaction of the GPCR activation of 
phosphoinositide-3 kinase (PI3K) and Akt (Hammond, et al., 2000). When PI3K is 
activated and subsequent activation of Akt occurs. This protein then phosphorylates BAD, 
increases its affinity for 14-3-3. By increasing this affinity, BAD can no longer form a 
heterodimer with Bcl-XL (anti-apoptotic), which allows it to inhibit the actions of Bax, a 
pro-apoptotic protein (see Figure 15) (Hammond, et al., 2000; Lodish, et al., 2004). This 
therefore allows for the inhibition of the subsequent apoptosis pathway and permits the cell 
to survive. Similarly activation of Ras by these GPCR’s leads to downstream mitogen 
activating protein kinase (MAPK) cascade and cell survival (Hammond, et al., 2000; 
Lodish, et al., 2004) 
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Figure 15: Apoptosis Pathway. A representation of the pathways that are activated in 
the apoptotic (absence of trophic factors) pathway (A) and the inhibition of the same 
pathway in the presence of trophic factors (B) (Lodish, et al., 2004) 
 
 
Another suggested mechanism for increased proliferation by CXCL8 is by 
transactivation of the epidermal growth factor receptor (EGFR) by G-protein coupled 
receptor (GPCR) stimulation (Itoh, et al., 2004, Luppi, et al., 2006). It has been previously 
reported that CXCL8 causes an increase in matrix metalloprotease 2 and 9 (MMP-2 and 
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MMP-9) (Li, et al., 2003; Li, et al., 2005; Patel, et al., 2005; Handsley and Edwards, 
2005). It is then feasible that stimulation of CXCR2 by CXCL8 would cause an increase in 
levels of MMP-2 and MMP-9. These MMPs would then cleave the membrane bound 
epidermal growth factor (EGF), which would subsequently activate its receptor, EGFR 
(Itoh, et al., 2004; Luppi, et al., 2006). EGF, a known growth factor has been found to 
work via the mitogen activating protein kinase (MAPK) cascade to increase cellular 
proliferation among other cellular changes (Lodish, et al., 2004).  
 
 
4.4  CXCL8 Expression and Metastasis 
 
 Metastasis occurs when tumors gain the ability to invade into other nearby tissues 
or into circulation to migrate to distant sites in the body. Along with increased 
proliferation, CXCL8 has been implicated in the phenomenon of tumor cell metastasis as 
well, with increased CXCL8 levels leading to a higher incidence of metastasis (Yuan, et 
al., 2000; Li, et al., 2005; Li, et al., 2003; Zhu, et al., 2004; Huang, et al., 2002; Itoh, et al., 
2005; Opdenakker and Van Damme, 2004, Luppi, et al., 2006). Results from the current 
study support this hypothesis. When in vitro experiments were performed with the HN12 
cell line it was found that the HN12-shL8 knockdown line had significantly fewer numbers 
of cells migrating across the semi-permeable membrane. Similarly, when this same 
membrane was covered with a solution that mimics the composition of the extracellular 
matrix (ECM), the number of cells that invaded through this layer for the HN12-shL8 
knockdown line was far fewer than for the control cell line. When the same migration 
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assay was performed for the HN4 cells, the HN4-CXCL8 overexpressing line had 
significantly more cells migrating across the membrane than did the control. This 
difference was not as profound as for the HN12 cells however. An invasion assay was not 
performed for the HN4 cells due to the low number of cells that migrated with the semi-
permeable membrane alone. It was believed that adding the layer of Matrigel to the 
membrane would completely inhibit any sort of migration or invasion.  
 The increase in metastasis by CXCL8 has been attributed to several downstream 
signaling pathways which are predominantly associated with activation of the CXCR2 
receptor (Strieter, et al., 2005; Addison, et al., 2000; Heidemann, et al., 2003; Varney, et 
al., 2006). This GPCR has been shown to activate Rac and Rho as well as the MAPK 
pathway mentioned earlier (Strieter, et al., 2005; Bizzarri, et al., 2006). Rac and Rho, 
along with increased intracellular Ca2+ influx, function to allow cellular migration through 
rearrangement of the actin cytoskeleton. Rac is involved in lamellipodia formation and 
Rho with focal adhesion and stress fiber assembly. Together, these two play a key role in 
the cell motility that is needed for tumor metastasis. 
 Although one would assume that there is no link between the mechanisms of 
cellular proliferation and cellular migration and invasion, it seems as though this is not the 
case. The common denominator underlying these two mechanisms is the matrix 
metalloproteases (MMPs) that are upregulated in response to CXCL8 binding to its 
receptor. As mentioned earlier, when CXCL8 binds to its G-protein coupled receptor 
(GPCR) it activates a signaling cascade that leads to an increase in transcription and 
subsequent translation of the gene for MMP-2 and MMP-9 (Li, et al., 2003; Li, et al., 
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2005; Patel, et al., 2005; Handsley and Edwards, 2005). MMP-2 and -9 are part of a group 
of proteases that specifically break down and degrade type-IV collagen, which is a major 
component of the basement membrane (Li, et al., 2003; Li, et al., 2005; Patel, et al., 2005; 
Handsley and Edwards, 2005). By breaking down this membrane, these specific MMPs 
help to pave the way for the migration of cells. Another interesting finding is that by Van 
den Steen, et al., (2000) which shows that post-translational CXCL8 processing by MMP-9 
leads to a 10-27 fold increase in CXCL8 activation. This would imply that there is a 
positive feedback loop between CXCL8 and MMP-9, which would not only increase the 
amount of MMP which can degrade the extracellular matrix, but may also be a cause of the 
increased proliferation via transactivation of epidermal growth factor receptor (EGFR), as 
mentioned earlier.  
 
4.5  HNSCC Model Limitations 
 The HNSCC model that was used for the current study has certain limitations that 
could have possible effects on the outcomes of the experiments performed on them. 
Although both the HN4 and HN12 cell lines were derived from the same patient, their 
genetic background is not as similar as we would hope. Microarray analysis performed by 
Miyazaki, et al., (2006) shows that approximately 30 genes were upregulated and 30 genes 
were downregulated in HN12 metastatic cells when compared to HN4 primary tumor cells. 
These genes include an assortment of growth factors and tumor antigens as well as 
molecules involved in signal transduction, angiogenesis, cell survival, transcriptional 
regulation and metabolism. These variables could possibly have an effect on CXCL8 that 
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is not well understood. For example, they may act synergistically to enhance the effects of 
CXCL8 or perhaps inhibit its actions.  
 Also, the fact that this is an in vitro study in itself has limitations. With this sort of 
study only one specific tissue is tested outside of the host organisms body. This has its 
downfalls because there may be factors which affect and interact with CXCL8 that would 
be present in in vivo studies, but which are absent in ours. With that being said, since we 
have only just begun to look at the effects of CXCL8 on tumorigenesis, an in vitro study is 
a good starting point, which would give a general idea of the trends that we should expect 
to see when the experiments progress into an in vivo study. Previous studies in both in vitro 
and in vivo models have reported similar results as our own in respect to CXCL8 function 
and effects on tumor progression. These studies, however, have not been performed in 
HNSCC, and mainly focused on tumors of the lung, colon and prostate where 
inflammation seems to play a role (Yuan, et al., 2000; Li, et al., 2005; Li, et al., 2003; Zhu, 
et al., 2004; Huang, et al., 2002; Itoh, et al., 2005; Opdenakker and Van Damme, 2004, 
Luppi, et al., 2006). 
 
4.6  shRNA Limitations 
 shRNA has proved to be an effective method for testing biological function of 
specific genes by degradation of their mRNA. In the current study using our shRNA 
protocol we were able to decrease the levels of expressed CXCL8 by approximately 2.5 
fold. Previous shRNA studies performed in our lab on CXCL5, another CXC chemokine,  
showed a decrease in expression of almost 15 fold (Miyazaki, et al., 2006). This is a much 
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more drastic difference than the decrease observed in the current study. The question then 
arises of how, if possible, could the knockdown of CXCL8 be performed in a greater, more 
efficient manner. It is possible that by varying the conditions of the actual transfection 
itself, the cells would be more likely to take up the plasmid with the incorporated shL8 
sequence. Also, reconstructing several different shL8 sequence and testing each separately, 
although costly, could help to find an optimal level of downregulation of the gene of 
interest. This sequencing issue may be responsible for less drastic knockdown of CXCL8 
than that seen in CXCL5. Perhaps the RNA specificity was not as great as expected.  
 shRNA mediated gene downregulation is one of the newer methods of decreasing 
gene expression. This procedure works great for in vitro studies, however, the use of 
shRNA for in vivo studies is fairly new and has a greater chance for failure. When 
transfecting the shRNA containing plasmid into a cell culture, one of the main concerns is 
the ability to cross the plasma membrane of the cell. When working with an in vivo model 
more factors come into play. The silencing depends on the efficiency of the delivery as 
well as the retention of the plasmid in the tissue of interest. Another concern is the stability 
of the plasmid once placed in the system (www.ambion.com, 2007).  
 Another method that has been used to inhibit specific protein function, other than 
gene knockdown, is the antibody method. By using specific antibodies to bind to and 
sequester the active protein or comepitively binding to and inhibiting its receptor the 
biological functions of the protein of choice can be effectively elucidated. 
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4.7  Future Studies 
 In the current study CXCL8 has been shown to play a role in the increased 
proliferation and migration/invasion that is associated with certain types of cancers. 
Another known function of CXCL8 in tumor progression has to do with its involvement in 
neovascularization of tumors (Yuan, et al., 2000; Li, et al., 2005; Li, et al., 2003; Zhu, et 
al., 2004; Huang, et al., 2002; Itoh, et al., 2005; Opdenakker and Van Damme, 2004, 
Luppi, et al., 2006). A possible future direction for this current study would be to perform 
in vitro angiogenesis assays using human umbilical vein endothelial cells (HUMVEC) and 
testing to see if CXCL8 causes increased migration of these cells towards the secreting 
HN12 or HN4 cells. 
 Once the results of this assay are confirmed in vitro these assays, including 
proliferation, migration and angiogenesis can be tested on an in vivo mouse model. By 
using the xenograft method of introducing tumors to the tongue or cheek of the mouse it 
would be possible to test in vivo to see if CXCL8 plays a role in tumor proliferation, 
metastasis and increased neovascularization.  
 As mentioned earlier, rather than using shRNA to knockdown our gene of interest, 
perhaps using antibodies directed to CXCL8 or its receptors, CXCR1 and CXCR2, would 
be more effective, or could be run in parallel to confirm the results of the shRNA study. 
Also, using the antibody method could allow us to inhibit known downstream molecules 
that are activated or inhibited by CXCL8 so as to elucidate in more detail the signal 
transduction pathways that are involved in this process. 
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